In this study, we demonstrate the utility of whole-slide CyCIF (tissue-based cyclic immunofluorescence) imaging for characterizing immune cell infiltrates in immune checkpoint inhibitor (ICI)-induced dermatologic adverse events (dAEs). We analyzed six cases of ICI-induced dAEs, including lichenoid, bullous pemphigoid, psoriasis, and eczematous eruptions, comparing immune profiling results obtained using both standard immunohistochemistry (IHC) and CyCIF. Our findings indicate that CyCIF provides more detailed and precise single-cell characterization of immune cell infiltrates than IHC, which relies on semi-quantitative scoring by pathologists. This pilot study highlights the potential of CyCIF to advance our understanding of the immune environment in dAEs by revealing tissue-level spatial patterns of immune cell infiltrates, allowing for more precise phenotypic distinctions and deeper exploration of disease mechanisms. By demonstrating that CyCIF can be performed on friable tissues, such as bullous pemphigoid, we provide a foundation for future studies to examine the drivers of specific dAEs using larger cohorts of phenotyped toxicity and suggest a broader role for highly multiplexed tissue imaging in phenotyping the immune mediated disease that they resemble.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10104016 | PMC |
http://dx.doi.org/10.1101/2023.04.03.535435 | DOI Listing |
Neoplasia
December 2024
Felsenstein Medical Research Center, Beilinson Campus, Petah Tikva, Israel; Tel Aviv University, Faculty of Medicine and Health Sciences, Tel Aviv, Israel; Rabin Medical Center, Beilinson Campus, Petah Tikva, Israel; Davidoff Cancer Center, Beilinson Campus, Petah Tikva, Israel. Electronic address:
Triple-negative breast cancer (TNBC) is an aggressive subtype that accounts for 10-15 % of breast cancer. Current treatment of high-risk early-stage TNBC includes neoadjuvant chemo-immune therapy. However, the substantial variation in immune response prompts an urgent need for new immune-targeting agents.
View Article and Find Full Text PDFPLoS Pathog
December 2024
Amsterdam UMC, location University of Amsterdam, Experimental Immunology, Amsterdam, The Netherlands.
The gastrointestinal tract is a prominent portal of entry for HIV-1 during sexual or perinatal transmission, as well as a major site of HIV-1 persistence and replication. Elucidation of underlying mechanisms of intestinal HIV-1 infection are thus needed for the advancement of HIV-1 curative therapies. Here, we present a human 2D intestinal immuno-organoid system to model HIV-1 disease that recapitulates tissue compartmentalization and epithelial-immune cellular interactions.
View Article and Find Full Text PDFPLoS One
December 2024
Department of Pharmacy Practice, Faculty of Pharmacy, Airlangga University, Surabaya, Indonesia.
Food allergies are a global health problem that continues to grow annually, with a prevalence of more than 10%. Shrimp allergy is the most common and life-threatening allergy. There is no cure for food allergies, but shrimp allergen extract (SAE) offers promise as a treatment through allergen-specific immunotherapy (AIT).
View Article and Find Full Text PDFMol Oncol
December 2024
Thumbay Research Institute for Precision Medicine, Gulf Medical University, Ajman, United Arab Emirates.
Hypoxia is known to induce reprogramming of glucose metabolism in cancer. However, the impact of hypoxia on global metabolism remains poorly understood. Here, using the systems approach, we evaluated the potential crosstalk between hypoxia and global metabolism using data from > 2000 breast tumors.
View Article and Find Full Text PDFVestn Otorinolaringol
December 2024
Dagestan State Medical University, Makhachkala, Russia.
Unlabelled: This paper presents the results of the evaluation of cellular and humoral immunity in chronic purulent otitis media (CPOM), as well as cytokine status, and studies the effect of azoximers bromide on the immunity system in CPOM.
Objective: To study the clinical and immunologic effectiveness of azoximer bromide in the postoperative period during tympanoplasty in CPOM patients.
Material And Methods: Forty-nine patients with mesotympanitis and epitympanitis were examined.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!